Literature DB >> 25096192

Beating the odds: extreme long-term survival with glioblastoma.

Wenya Linda Bi1, Rameen Beroukhim1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25096192      PMCID： PMC4136904          DOI： 10.1093/neuonc/nou166

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  20 in total

1.  Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss.

Authors:  Y Ino; M C Zlatescu; H Sasaki; D R Macdonald; A O Stemmer-Rachamimov; S Jhung; D A Ramsay; A von Deimling; D N Louis; J G Cairncross
Journal:  J Neurosurg       Date:  2000-06       Impact factor: 5.115

2.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.

Authors:  Shideng Bao; Qiulian Wu; Roger E McLendon; Yueling Hao; Qing Shi; Anita B Hjelmeland; Mark W Dewhirst; Darell D Bigner; Jeremy N Rich
Journal:  Nature       Date:  2006-10-18       Impact factor: 49.962

3.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.

Authors:  Houtan Noushmehr; Daniel J Weisenberger; Kristin Diefes; Heidi S Phillips; Kanan Pujara; Benjamin P Berman; Fei Pan; Christopher E Pelloski; Erik P Sulman; Krishna P Bhat; Roel G W Verhaak; Katherine A Hoadley; D Neil Hayes; Charles M Perou; Heather K Schmidt; Li Ding; Richard K Wilson; David Van Den Berg; Hui Shen; Henrik Bengtsson; Pierre Neuvial; Leslie M Cope; Jonathan Buckley; James G Herman; Stephen B Baylin; Peter W Laird; Kenneth Aldape
Journal:  Cancer Cell       Date:  2010-04-15       Impact factor: 31.743

4.  An extent of resection threshold for newly diagnosed glioblastomas.

Authors:  Nader Sanai; Mei-Yin Polley; Michael W McDermott; Andrew T Parsa; Mitchel S Berger
Journal:  J Neurosurg       Date:  2011-03-18       Impact factor: 5.115

5.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

Authors:  Roel G W Verhaak; Katherine A Hoadley; Elizabeth Purdom; Victoria Wang; Yuan Qi; Matthew D Wilkerson; C Ryan Miller; Li Ding; Todd Golub; Jill P Mesirov; Gabriele Alexe; Michael Lawrence; Michael O'Kelly; Pablo Tamayo; Barbara A Weir; Stacey Gabriel; Wendy Winckler; Supriya Gupta; Lakshmi Jakkula; Heidi S Feiler; J Graeme Hodgson; C David James; Jann N Sarkaria; Cameron Brennan; Ari Kahn; Paul T Spellman; Richard K Wilson; Terence P Speed; Joe W Gray; Matthew Meyerson; Gad Getz; Charles M Perou; D Neil Hayes
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

6.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

Authors:  Olivier L Chinot; Wolfgang Wick; Warren Mason; Roger Henriksson; Frank Saran; Ryo Nishikawa; Antoine F Carpentier; Khe Hoang-Xuan; Petr Kavan; Dana Cernea; Alba A Brandes; Magalie Hilton; Lauren Abrey; Timothy Cloughesy
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

7.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.

Authors:  Heidi S Phillips; Samir Kharbanda; Ruihuan Chen; William F Forrest; Robert H Soriano; Thomas D Wu; Anjan Misra; Janice M Nigro; Howard Colman; Liliana Soroceanu; P Mickey Williams; Zora Modrusan; Burt G Feuerstein; Ken Aldape
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

8.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

9.  A proposed classification system that projects outcomes based on preoperative variables for adult patients with glioblastoma multiforme.

Authors:  Kaisorn Chaichana; Scott Parker; Alessandro Olivi; Alfredo Quiñones-Hinojosa
Journal:  J Neurosurg       Date:  2010-05       Impact factor: 5.115

10.  IDH1 and IDH2 mutations in gliomas.

Authors:  Hai Yan; D Williams Parsons; Genglin Jin; Roger McLendon; B Ahmed Rasheed; Weishi Yuan; Ivan Kos; Ines Batinic-Haberle; Siân Jones; Gregory J Riggins; Henry Friedman; Allan Friedman; David Reardon; James Herndon; Kenneth W Kinzler; Victor E Velculescu; Bert Vogelstein; Darell D Bigner
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 176.079
View more
  24 in total

1.  Glioblastoma cells vampirize WNT from neurons and trigger a JNK/MMP signaling loop that enhances glioblastoma progression and neurodegeneration.

Authors:  Marta Portela; Varun Venkataramani; Natasha Fahey-Lozano; Esther Seco; Maria Losada-Perez; Frank Winkler; Sergio Casas-Tintó
Journal:  PLoS Biol       Date:  2019-12-17       Impact factor: 8.029

2.  PARP-1-Targeted Radiotherapy in Mouse Models of Glioblastoma.

Authors:  Stephen A Jannetti; Giuseppe Carlucci; Brandon Carney; Susanne Kossatz; Larissa Shenker; Lukas M Carter; Beatriz Salinas; Christian Brand; Ahmad Sadique; Patrick L Donabedian; Kristen M Cunanan; Mithat Gönen; Vladimir Ponomarev; Brian M Zeglis; Mark M Souweidane; Jason S Lewis; Wolfgang A Weber; John L Humm; Thomas Reiner
Journal:  J Nucl Med       Date:  2018-03-23       Impact factor: 10.057

3.  Plasma amino acids indicate glioblastoma with ATRX loss.

Authors:  Ernest Jan Bobeff; Dorota Szczesna; Michał Bieńkowski; Karolina Janczar; Malgorzata Chmielewska-Kassassir; Karol Wiśniewski; Wielisław Papierz; Lucyna Alicja Wozniak; Dariusz Jan Jaskólski
Journal:  Amino Acids       Date:  2021-01-04       Impact factor: 3.520

4.  Targeted Brain Tumor Radiotherapy Using an Auger Emitter.

Authors:  Giacomo Pirovano; Stephen A Jannetti; Lukas M Carter; Ahmad Sadique; Susanne Kossatz; Navjot Guru; Paula Demétrio De Souza França; Masatomo Maeda; Brian M Zeglis; Jason S Lewis; John L Humm; Thomas Reiner
Journal:  Clin Cancer Res       Date:  2020-02-17       Impact factor: 12.531

5.  Design, synthesis, and evaluation of cisplatin-containing EGFR targeting bioconjugates as potential therapeutic agents for brain tumors.

Authors:  Rolf F Barth; Gong Wu; W Hans Meisen; Robin J Nakkula; Weilian Yang; Tianyao Huo; David A Kellough; Pravin Kaumaya; Claudia Turro; Lawrence M Agius; Balveen Kaur
Journal:  Onco Targets Ther       Date:  2016-05-10       Impact factor: 4.147

6.  FBLN4 as candidate gene associated with long-term and short-term survival with primary glioblastoma.

Authors:  Fubin Li; Yiping Li; Kewei Zhang; Ye Li; Ping He; Yujia Liu; Hongyan Yuan; Honghua Lu; Jinxiang Liu; Songtian Che; Zhenju Li; Li Bie
Journal:  Onco Targets Ther       Date:  2017-01-16       Impact factor: 4.147

7.  Drug Conjugates for Targeting Eph Receptors in Glioblastoma.

Authors:  Puja Sharma; Callie Roberts; Denise Herpai; Izabela D Fokt; Waldemar Priebe; Waldemar Debinski
Journal:  Pharmaceuticals (Basel)       Date:  2020-04-23

8.  Sex-specific impact of patterns of imageable tumor growth on survival of primary glioblastoma patients.

Authors:  Paula Whitmire; Cassandra R Rickertsen; Andrea Hawkins-Daarud; Eduardo Carrasco; Julia Lorence; Gustavo De Leon; Lee Curtin; Spencer Bayless; Kamala Clark-Swanson; Noah C Peeri; Christina Corpuz; Christine Paula Lewis-de Los Angeles; Bernard R Bendok; Luis Gonzalez-Cuyar; Sujay Vora; Maciej M Mrugala; Leland S Hu; Lei Wang; Alyx Porter; Priya Kumthekar; Sandra K Johnston; Kathleen M Egan; Robert Gatenby; Peter Canoll; Joshua B Rubin; Kristin R Swanson
Journal:  BMC Cancer       Date:  2020-05-19       Impact factor: 4.430

9.  Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas.

Authors:  Hao Zhou; Ken Chang; Harrison X Bai; Bo Xiao; Chang Su; Wenya Linda Bi; Paul J Zhang; Joeky T Senders; Martin Vallières; Vasileios K Kavouridis; Alessandro Boaro; Omar Arnaout; Li Yang; Raymond Y Huang
Journal:  J Neurooncol       Date:  2019-01-19       Impact factor: 4.506

Review 10.  Receptor-Targeted Glial Brain Tumor Therapies.

Authors:  Puja Sharma; Waldemar Debinski
Journal:  Int J Mol Sci       Date:  2018-10-25       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.